Comparing the current results to its competitors, Enveric Biosciences Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, slower than the combined decrease of the ENVB's competitors by -8.41 %, recorded in the same quarter.
Enveric Biosciences Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industries, which are characterized by rapidly advancing technologies and intense competition. It faces potential competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research institutions. The company focuses on developing novel psychedelic-inspired drug candidates for mental illnesses and unmet medical needs. It plans to partner with pharmaceutical and biotechnology companies to develop and commercialize these medicines. Competitors may develop and commercialize medicines that are safer, more effective, have fewer side effects, are more convenient, or less expensive, and may obtain regulatory approval more rapidly, potentially reducing the company's commercial opportunities.
September 17, 2025
In an era marked by significant advancements in the field of medicinal chemistry, the ability to innovate bioproduction methods stands as a beacon of hope for drug discovery, particularly in the domain of neuropsychiatric disorders. Enveric Biosciences Inc. (NASDAQ: ENVB), a biotechnology enterprise based in Cambridge, Massachusetts, has recently garnered attention within the scientific community through the publication of two peer-reviewed articles that detail pioneering bioproduction strategies aimed at fostering the development of neuroplastogenic small molecules. The escalating global burden of psychiatric and neurological disorders necessitates the urgent development of novel therapeutic strategies. Env...
January 31, 2025
: Enveric Biosciences, a biotechnology company focused on innovative small-molecule therapeutics targeting neuroplasticity, has made significant strides in the development of its lead drug candidate, EB-003. Recent announcements include a Notice of Allowance (NOA) from the United States Patent and Trademark Office (USPTO) and comprehensive preclinical pharmacokinetic (PK) studies indicating favorable oral bioavailability and brain penetration without hallucinogenic effects. This article reviews the implications of these developments for the treatment of depression, anxiety, and addiction disorders, highlighting the potential of EB-003 as a pioneering neuroplastogenic agent. The growing global prevalence o...
December 2, 2024
Enveric Biosciences: Navigating A New Patent Milestone Amidst Market Challenges In a landscape characterised by dynamic shifts and competitive forces, Enveric Biosciences (NASDAQ: ENVB), a Cambridge-based biotechnology firm, has remarkably succeeded in securing additional intellectual property protections. Recently, the United States Patent and Trademark Office (USPTO) granted Enveric two significant patents, namely Nos. 12,133,856 and 12,138,276, which are focused on the company’s pioneering EVM301 and EVM201 series of neuroplastogenic small-molecule therapeutics. These innovations aim to transform the treatment landscape for anxiety, depression, and addiction disorders, a bold stride that underscores Env...
July 15, 2024
CAMBRIDGE, Mass. In a significant stride towards alleviating the suffering of patients undergoing radiation therapy, Enveric Biosciences (NASDAQ: ENVB), a pioneer in the field of biotechnology dedicated to the development of novel neuroplastogens for treating neuropsychiatric disorders, and Aries Science and Technology (Aries), renowned for their innovative encapsulation technologies, have entered into a licensing agreement. This partnership focuses on the clinical development of Enveric s patented topical product designed to treat radiation dermatitis, a prevalent and often debilitating side effect of radiation treatment. Radiation dermatitis is a common condition that affects a large proportion of patien...
June 25, 2024
Enveric Biosciences Sharpen Focus on Neuroplastogenic Therapies with New Lead Candidate EB-003Enveric Biosciences (NASDAQ: ENVB), the Cambridge-based biotechnology innovator, recently announced a pivotal strategic shift, shining a spotlight on their promising developmental candidate, EB-003. The company s renewed focus on this first-in-class neuroplastogenic small-molecule therapy underscores its commitment to pioneering treatments for debilitating mental health conditions such as depression, anxiety, and addiction disorders. The Deep Dive into Enveric s Strategic OutlookIn the fast-evolving field of biotechnology, Enveric Biosciences is making waves with its groundbreaking approach to neuroplastogenics. Th...
March 19, 2024
Enveric Biosciences Signs Term Sheets for Out-Licensing Neuroplastogenic Compounds and Unveils Promising Drug Candidates for Mental Health DisordersEnveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on developing innovative small-molecule therapeutics for depression, anxiety, and addiction disorders, has made significant advancements in its drug discovery and out-licensing efforts. The company recently signed two non-binding term sheets with an undisclosed biotechnology company to explore the licensing of cannabinoid-COX-2 conjugate compounds for both pharmaceutical and non-pharmaceutical applications in joint disease. Additionally, Enveric Biosciences announced the discovery of multiple nov...
February 23, 2024
Enveric Biosciences, a forward-thinking biotechnology company, has made significant strides in the field of cancer treatment through the development of novel neuroplastogenic small-molecule therapeutics. As part of their ongoing commitment to revolutionizing the treatment landscape, Enveric recently announced the sale of one of their cancer-related patent portfolios. This development comes as Enveric continues to dedicate resources towards the advancement of lead candidates such as EB-003, which hold promising potential in the fight against depression, anxiety, and addiction disorders.Exploring Enveric Biosciences Cancer-Targeting Intellectual Property:Enveric s decision to sell one of their cancer-related ...
February 21, 2024
Enveric Biosciences Unveils Novel Compounds for Mental Health Disorders: A Step Towards Breakthrough Neuroplastogenic Therapeutics Enveric Biosciences, a prominent biotechnology company, has recently unveiled a library of preclinical compounds targeting mental health disorders. The company s advanced Psybrary platform and proprietary computational chemistry and artificial intelligence (AI) drug-discovery system, PsyAI, were utilized for the discovery of these promising novel compounds. This breakthrough could pave the way for the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders.Enveric Biosciences is at the forefront of pharmaceutic...
December 28, 2023
Cambridge, Mass. - Enveric Biosciences (NASDAQ: ENVB), a renowned biotechnology company focused on developing innovative small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, has announced the selection of EB-003 as its lead drug candidate from the EVM301 Series. With groundbreaking potential, EB-003 has the capability to revolutionize the treatment of various mental health disorders.The team at Enveric Biosciences is dedicated to addressing the unmet medical needs of patients suffering from depression, anxiety, and addiction. Through their extensive research and development efforts, they have developed the EVM301 Series, a range of next-generation neuroplastogenic sm...
Pasithea Therapeutics Corp's business model revolves around the development and commercialization of therapeutic treatments for sleep disorders and other related conditions.
Inmed Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of cannabinoid-based therapies for various diseases. The company's business model revolves around conducting research and development to identify novel drug candidates, conducting pre-clinical and clinical trials to test the safety and efficacy of these candidates, and seeking partnerships or collaborations with other pharmaceutical companies for the further development and commercialization of successful therapies. By leveraging advancements in cannabinoid science, Inmed Pharmaceuticals aims to provide innovative medical treatments for unmet medical needs.
Evoke Pharma Inc operates as a specialty pharmaceutical company focusing on the development and commercialization of drugs for the treatment of gastrointestinal disorders. Their business model involves researching, developing, and marketing innovative pharmaceutical products to address unmet medical needs in the gastrointestinal market.
Bright Minds Biosciences Inc is a biotechnology company that focuses on developing novel therapies for neuropsychiatric diseases. Their business model involves conducting research and development to discover and develop proprietary drug candidates, with the aim of partnering or licensing them to pharmaceutical companies for further clinical development and commercialization.
Sources:
Enveric Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Enveric Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
